Home › NCT07584434

A Phase 1, First-in-human Study of VX-433

A Phase 1, First-in-human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VX-433 and Its Effects on the Pharmacokinetics of Midazolam and Bupropion

Who can join

Ages 18 to 55 · All sexes · Healthy volunteers welcome

Key Inclusion Criteria:

* Body mass index (BMI) of 18.0 to 30.0 kilogram per meter square (kg/m2), inclusive
* A total body weight of more than (\>) 50 kg
* Nonsmoker or ex-smoker for at least 3 months before screening with current nonsmoking status confirmed by urine or blood cotinine at screening

Key Exclusion Criteria:

* History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug
* Any condition possibly affecting drug absorption
* For female participants: of childbearing potential, pregnant, breastfeeding, or planning to become pregnant or donate ova during the study or within 90 days after last dose of study drug

Other protocol defined Inclusion/Exclusion criteria will apply.

About the study

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-433 following single and multiple ascending doses, as well as to assess the effect of VX-433 on the PK of midazolam, bupropion, and hydroxybupropion.

What is being tested

• VX-433 (drug)
• Placebo (drug)
• Midazolam (drug)
• Bupropion (drug)

Sponsor: Vertex Pharmaceuticals Incorporated · Participants: 118 · Started: May 21, 2026

Contact the study team

• Medical Information · Phone: 617-341-6777

Official record on ClinicalTrials.gov — NCT07584434

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.